Wegovy-maker Novo Nordisk has implemented a global hiring freeze, which covers job roles that are not critical for its ...

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Novo Nordisk is to freeze hiring in an effort to control costs at the drug maker. The halt will apply across all markets and ...

Key Takeaways Novo Nordisk's blockbuster weight-loss drug, Wegovy, received Food and Drug Administration approval to treat a ...

Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, Reuters writes ...

Shares of Novo Nordisk ( NVO 4.81%), the Danish pharmaceuticals company famed for Ozempic and Wegovy weight loss drugs, ...

The firm was granted U.S. approval for the treatment of metabolic dysfunction-associated steatohepatitis in adults with ...

Data to highlight the impact of Wegovy® (semaglutide 2.4 mg) on atrial fibrillation - a common heart rhythm condition - in people living with obesity (SELECT study)Additional Rybelsus® and Ozempic® da ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Novo Nordisk shares climbed after the U.S. Food and Drug Administration approved a new indication for the Danish drugmaker’s ...

Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals. Click here to read why I rate ...